First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation.
CER-001
COVID-19
HDL
case-report
cytokines
inflammation
lipoprotein
proteomics
sepsis
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
23 Mar 2022
23 Mar 2022
Historique:
received:
09
02
2022
revised:
14
03
2022
accepted:
20
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
High-density lipoproteins (HDLs) have multiple endothelioprotective properties. During SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and studies have described severe impairment of the functionality of HDL particles. Here, we report a multi-omic investigation of the first administration of recombinant HDL (rHDL) particles in a severe COVID-19 patient in an intensive care unit. Plasma ApoA1 increased and HDL-C decreased after each recombinant HDL injection, suggesting that these particles were functional in terms of reverse cholesterol transport. The proportion of large HDL particles also increased after injection of recombinant HDL. Shotgun proteomics performed on HDLs isolated by ultracentrifugation indicated that ApoA1 was more abundant after injections whereas most of the pro-inflammatory proteins identified were less abundant. Assessment of Serum amyloid A-1, inflammatory markers, and cytokines showed a significant decrease for most of them during recombinant HDL infusion. Our results suggest that recombinant HDL infusion is feasible and a potential therapeutic strategy to be explored in COVID-19 patients.
Identifiants
pubmed: 35453504
pii: biomedicines10040754
doi: 10.3390/biomedicines10040754
pmc: PMC9029957
pii:
doi:
Types de publication
Case Reports
Langues
eng
Subventions
Organisme : POE FEDER 2014-20
ID : RE0027601
Organisme : POE FEDER 2014-20
ID : RE20201437
Organisme : Université de La Réunion
ID : COVID-19 emergency seed funding
Références
PLoS One. 2020 Sep 24;15(9):e0239573
pubmed: 32970772
J Lipid Res. 2015 Aug;56(8):1519-30
pubmed: 25995210
Am Heart J. 2019 Feb;208:81-90
pubmed: 30580130
Ann Intensive Care. 2021 Jan 19;11(1):11
pubmed: 33469739
Sci Rep. 2021 Jan 27;11(1):2291
pubmed: 33504824
J Biol Chem. 2013 Jun 21;288(25):17947-53
pubmed: 23658016
J Exp Med. 1994 Sep 1;180(3):1025-35
pubmed: 8064223
J Lipid Res. 2015 Mar;56(3):703-712
pubmed: 25561459
Sci Rep. 2021 Mar 30;11(1):7217
pubmed: 33785815
Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1987-94
pubmed: 7583580
Circulation. 2009 Apr 21;119(15):2103-11
pubmed: 19349317
Crit Care Med. 2003 May;31(5):1359-66
pubmed: 12771603
Circ Res. 2016 Sep 2;119(6):751-63
pubmed: 27436846
J Intern Med. 2022 Mar;291(3):364-370
pubmed: 34761839
J Clin Invest. 1981 Mar;67(3):827-37
pubmed: 7204557
Infect Immun. 2000 May;68(5):2410-7
pubmed: 10768924
J Clin Invest. 1995 Dec;96(6):2882-91
pubmed: 8675659
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Biomedicines. 2021 Aug 26;9(9):
pubmed: 34572275
Trends Cardiovasc Med. 2003 Aug;13(6):226-31
pubmed: 12922018
J Clin Lipidol. 2020 May - Jun;14(3):297-304
pubmed: 32430154
Int J Cardiol. 2019 Jun 15;285:53-58
pubmed: 30857841
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2071-7
pubmed: 18617650
J Biol Chem. 2001 Sep 14;276(37):34480-5
pubmed: 11432865
Front Endocrinol (Lausanne). 2021 Jun 23;12:611526
pubmed: 34248834
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):763-72
pubmed: 10712402
Thromb Haemost. 1998 Aug;80(2):316-20
pubmed: 9716159
Circulation. 2002 Mar 26;105(12):1399-402
pubmed: 11914243
Shock. 2018 Jul;50(1):66-70
pubmed: 29049133
J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):315-23
pubmed: 22067613
Atherosclerosis. 2020 Oct;311:13-19
pubmed: 32919280
Clin Proteomics. 2019 Jul 16;16:29
pubmed: 31341447
Sci Rep. 2017 Nov 15;7(1):15606
pubmed: 29142235
Atherosclerosis. 2014 Jan;232(1):110-8
pubmed: 24401224
Clin Chem. 2001 Feb;47(2):266-74
pubmed: 11159775
J Clin Exp Cardiolog. 2011 Dec 22;2(172):
pubmed: 23227448
J Am Coll Cardiol. 2009 Mar 17;53(11):962-71
pubmed: 19281927
Anesthesiology. 2020 Apr;132(4):825-838
pubmed: 32101976
Atherosclerosis. 2009 Oct;206(2):611-6
pubmed: 19375079
FASEB J. 2020 Aug;34(8):9843-9853
pubmed: 32588493
Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H866-73
pubmed: 19561306
Biomed Pharmacother. 2022 Jan;145:112420
pubmed: 34801852
J Trauma Acute Care Surg. 2012 Jun;72(6):1576-83
pubmed: 22695425
Clin Drug Investig. 2017 May;37(5):483-491
pubmed: 28213743
Atherosclerosis. 2012 Jun;222(2):390-4
pubmed: 22456230
Crit Care. 2020 Apr 7;24(1):134
pubmed: 32264946
Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2619-2627
pubmed: 34353699
Intensive Care Med. 2009 Nov;35(11):1877-85
pubmed: 19669126
Ann Intensive Care. 2019 Jun 13;9(1):68
pubmed: 31197574
JAMA Cardiol. 2018 Sep 1;3(9):815-822
pubmed: 30046828
J Clin Lipidol. 2021 Nov-Dec;15(6):796-804
pubmed: 34802985
Atherosclerosis. 2002 Mar;161(1):1-16
pubmed: 11882312
J Lipid Res. 2020 Jul;61(7):1128-1139
pubmed: 32404332
Ann Intensive Care. 2017 Dec;7(1):60
pubmed: 28589535
Curr Cardiol Rep. 2018 Jun 21;20(8):66
pubmed: 29926215
Ann Intern Med. 2021 Jul;174(7):1022-1025
pubmed: 33646847
Crit Care Med. 2005 Aug;33(8):1688-93
pubmed: 16096442
Br J Pharmacol. 2013 Jun;169(3):493-511
pubmed: 23488589
Clin Chim Acta. 2020 Nov;510:105-110
pubmed: 32653486
J Lipid Res. 2010 Sep;51(9):2695-705
pubmed: 20495214
Biol Chem. 2015 Jan;396(1):53-60
pubmed: 25205725
Circulation. 2009 Nov 24;120(21):2095-104
pubmed: 19901191
Antioxidants (Basel). 2020 Sep 29;9(10):
pubmed: 33003552
Metabolism. 2020 Jun;107:154243
pubmed: 32320740
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508